

Product Data Sheet

Product Name: Pacanalotamab

Cat. No.: GC74591

Chemical Properties

Cas. No. 2251756-52-0

Formula M.Wt

Solubility Storage

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

Pacanalotamab

Background

Pacanalotamab (AMG 420; BI-836909) is a bispecific T-cell engager (BiTE) targeting to BCMA and CD3E. BCMA refers to B cell maturation antigen, as Pacanalotamab redirecting T cells to BCMA expressing cells on the cell surface. Pacanalotamab conducts T-cell redirected lysis of human multiple myeloma (MM) cell lines.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Pacanalotamab (1 pg/mL-100 ng/mL; 24 h) induces BCMA-dependent tumor cell lysis via T cells activation. And Pacanalotamab induces dose-dependent redirected lysis of human multiple myeloma cell lines with EC90 values ranging from 16-810 pg/mL[1]. Pacanalotamab (100 ng/mL; 24 h) induces translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane, leading to apoptosis in MM.1R cells[1].

Pacanalotamab (50 µg/kg/day; i.v. or s.c.; for 18 days) exhibits anti-tumor activity in mouse NCI-H929 xenograft model[1]. Pacanalotamab (5 µg/kg/day; i.v. or s.c.) significantly prolongs survival of mouse in mouse orthotopic L-363 xenograft model[1]. Pacanalotamab (135 µg/kg/day for i.v. or 405 µg/kg/day for s.c.; up to 28 days) is well tolerated, and it decreases plasma cells in the bone marrow in macaque in toxicity studies[1].

References:

[1]. Hipp S, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. *Leukemia*. 2017 Aug;31(8):1743-1751.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA